Impact of PEG-GCSF in Breast Cancer Patients Undergoing Chemotherapy During the COVID-19 Pandemic: Single Center Experience and Literature Review.
Kioto YokoyamaNobuyasu YoshimotoSatoru TakayamaMasaki SakamotoKeisuke TomodaKen IshikawaMasakatsu YamashitaHiroto SuzukiRyosuke HosogiMasahiro TakahashiMari FukudaHisanori KaniPublished in: In vivo (Athens, Greece) (2024)
A potential role of PEG-GCSF in reducing suspected COVID-19 symptoms during chemotherapy, reducing the anxiety and need for hospital visits, thus improving patients' quality of life, is suggested. These insights could contribute to optimizing the care of breast cancer patients in situations like the current pandemic.
Keyphrases
- coronavirus disease
- sars cov
- patients undergoing
- end stage renal disease
- healthcare
- ejection fraction
- drug delivery
- newly diagnosed
- locally advanced
- chronic kidney disease
- peritoneal dialysis
- palliative care
- sleep quality
- squamous cell carcinoma
- prognostic factors
- chronic pain
- respiratory syndrome coronavirus
- rectal cancer
- adverse drug
- patient reported
- chemotherapy induced